Peripheral vascular disease articles

Programas de ejercicios en la enfermedad vascular periférica

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD). However, many participants randomized to exercise did not perceive changes, and sometimes even got worse.  These findings suggest a significant discrepancy between objective and perceived change in walking ability among PAD patients.   400 patients with peripheral artery disease

El tratamiento endovascular parece superior a la cirugía en aneurismas rotos

Abdominal Aortic Aneurysm during the Pandemic: Should They Be Operated or Deferred?

Some European societies have recommended deferring the treatment of infrarenal abdominal aortic aneurysm (AAA) ≥5.5 cm during the COVID-19 pandemic. However, these documents have also suggested optimal deferral times, and everything must be adjusted according to the transmission risk/risk of rupture balance. Annual risk of rupture can be estimated based on a prospective cohort published by

SOLACI PERIPHERAL | 7th Clinical Case: Percutaneous Treatment for Nutcracker Syndrome

New SOLACI PERIPHERAL clinical case to keep learning among peers! Dr. Carlos Eduardo Díniz Couto shares a “Nutcracker” case from Belo Horizonte, Brazil. This is the 7th clinical case presented by SOLACI Peripheral on the SOLACI website. This space is intended to further promote and share experiences and opinions in order to continue improving our

Subutilización del tratamiento médico en enfermedad vascular periférica

Which Type 2 Endoleaks Should We Intervene?

This work emphasizes the need to be conservative with type 2 endoleaks, and the need for long-term prospective information to learn about the advantages of intervention. The presence of type 2 endoleaks is associated with reintervention, as it was historically assumed that they increase the risk of sac rupture. However, this new research, published in

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny

ACC 2021 | VOYAGER PAD: utilidad del rivaroxaban luego de una angioplastia periférica

ACC 2021 | VOYAGER PAD: Usefulness of Rivaroxaban After Peripheral Angioplasty

Patients with peripheral vascular disease who undergo angioplasty in the lower limbs find benefit from treatment with rivaroxaban, according to the VOYAGER PAD study, presented at the scientific sessions of the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JACC. Patients with said disease present a higher risk of ischemic events not

SAFE-PAD: Dispositivos liberadores de paclitaxel en enfermedad periférica

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between all-cause mortality and paclitaxel-eluting devices in peripheral vascular disease. According to data from SAFE-PAD, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JAMA, there is no increase in mortality compared with conventional

ACC 2021 | Revive la denervación renal de la mano del RADIANCE-HTN TRIO

ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to this new study presented at ACC 2021 simultaneously published in the Lancet. Renal denervation reduces ambulatory daily systolic blood pressure by 8 mmHg vs 3 mmHg in the sham procedure branch.  This translates into a mean 4.5 mmHg

AHA 2019 | Treat Stroke to Target: terapia agresiva con estatinas post stroke

Can We Deal with Learning Curves in Acute Stroke?

When an interventional cardiology center, where interventional cardiology specialists work alongside neurologists and radiologists, start a thrombectomy program in acute stroke, results achieved are similar to those at an interventional neurology center. Mechanical thrombectomy has proven to be the best treatment option for acute ischemic stroke. However, it is not widely available, mainly due to

La clave para tratar strokes: saber cuando detenerse

The Key to Treating Stroke: Knowing When to Stop

With endovascular therapy as the standard of care in ischemic stroke and with a community of interventional cardiologists increasingly committed to assisting neurologists in providing 24/7 thrombectomy, staying informed is paramount. The number of thrombectomy attempts with retractable stent (>3) is associated with hemorrhagic transformation beyond age, baseline NIHSS (National Institutes of Health Stroke Scale)

Top